Skye falls as weight-loss drug misses main goal in mid-stage study

Skye Bioscience

06/10/2025 12:45

** Shares of drug developer Skye Bioscience SKYE.O fall 64.2% to $1.70 premarket

** Co says its experimental drug, nimacimab, did not meet the main goal of weight loss compared to placebo

** SKYE says the study results potentially indicate the need for higher dosing of the drug as a monotherapy

** Up to last close, stock has more than doubled YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))